{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperoxaluria%2C+Primary&page=2",
    "query": {
      "condition": "Hyperoxaluria, Primary",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperoxaluria%2C+Primary&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T11:07:51.994Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04580420",
      "title": "Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 1",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "DCR-PHXC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 28,
      "start_date": "2021-04-15",
      "completion_date": "2032-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580420"
    },
    {
      "nct_id": "NCT02794649",
      "title": "Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oxalate, Primary Hyperoxaluria, Microbiome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "VA New York Harbor Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-06",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02794649"
    },
    {
      "nct_id": "NCT00283387",
      "title": "Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "Betaine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "6 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2007-02",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-12-16",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283387"
    },
    {
      "nct_id": "NCT00875823",
      "title": "International Registry for Primary Hyperoxaluria",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Hyperoxaluria",
        "Nephrocalcinosis",
        "Kidney Stones"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2003-09",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Sacramento, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00875823"
    },
    {
      "nct_id": "NCT01037231",
      "title": "Phase 2/3 Oxabact Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "Oxalobacter formigenes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "OxThera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2009-12",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-05-15",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01037231"
    },
    {
      "nct_id": "NCT04555486",
      "title": "Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 3"
      ],
      "interventions": [
        {
          "name": "DCR-PHXC",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-09-14",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Rochester, Minnesota • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04555486"
    },
    {
      "nct_id": "NCT03116685",
      "title": "A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "Oxabact OC5 - Oxalobacter formigenes HC-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "OxThera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2018-01-09",
      "completion_date": "2021-04-15",
      "has_results": true,
      "last_update_posted_date": "2021-12-10",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03116685"
    },
    {
      "nct_id": "NCT03681184",
      "title": "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 1 (PH1)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lumasiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2018-11-27",
      "completion_date": "2024-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03681184"
    },
    {
      "nct_id": "NCT03905694",
      "title": "A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hyperoxaluria",
        "Primary Hyperoxaluria Type 1 (PH1)"
      ],
      "interventions": [
        {
          "name": "Lumasiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "0 Years to 5 Years"
      },
      "enrollment_count": 18,
      "start_date": "2019-04-22",
      "completion_date": "2024-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Houston, Texas",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03905694"
    },
    {
      "nct_id": "NCT00638703",
      "title": "Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "Oxalobacter formigenes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "OxThera",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2007-10",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2013-05-15",
      "last_synced_at": "2026-07-23T11:07:51.994Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00638703"
    }
  ]
}